Addiction is a chronic, relapsing brain disorder. While treatment can work to decrease morbidity and mortality associated with this disorder, a larger armamentarium of effective and accessible treatments for addiction is needed to significantly reduce the public health burden of addictive diseases. The present application requests support to develop a P30 Core Center in the National Institute on Drug Abuse (NIDA) in response to RFA-OD-09-005 [Supporting New Faculty Recruitment to Enhance Research Resources through Biomedical Research Core Centers]. The Center for Addiction Research (CAR) at the University of Texas Medical Branch (UTMB) and several regional institutions comprise the """"""""Core Center for Translational Addiction Sciences"""""""" (CCTAS). The CCTAS is uniquely positioned to create and integrate new knowledge, perspectives and tools across the boundaries of core strengths in chemistry, animal models, cellular and molecular biology, biomedical imaging and clinical science. We propose to recruit new faculty in medicinal chemistry, model genetics organisms (i.e., Drosophila), and clinical neurobiology to exploit this knowledge to discover new therapeutic approaches to addiction. The primary goal of the CCTAS is to mentor new faculty scientists to develop as independent translational scientists and to encourage their lifelong commitment to the search for better treatments for drug addiction. The CCTAS will assure faculty development through providing individualized and structured mentoring in a rich intellectual environment conducive for investigations in translational addiction sciences. With the recruitment of new faculty in chemistry, animal models and clinical neurobiology, we will make strides in creating new candidate molecules for medication and vaccine development, delve into the genetics of these disorders, and move our research advances closer to the patient bedside with the ultimate goal to improve lives. This P30 is responsive to NIDA's areas of interest in small molecule development for substance-related disorders, biomarkers, genetics, and vaccines and immunotherapies.

Public Health Relevance

New effective, accessible modalities for the treatment of drug addiction are desperately needed. We propose to recruit new faculty under the auspices of this P30 who will complement and expand an institutional community of trans-disciplinary scientists focused on translational discovery research for additive disorders. Our scientific mission is to exploit modern knowledge of addiction biology to discover new therapeutic approaches to improve the health status of affected individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
5P30DA028821-02
Application #
7936826
Study Section
Special Emphasis Panel (ZDA1-KXH-C (4A))
Program Officer
Babecki, Beth
Project Start
2009-09-30
Project End
2012-08-31
Budget Start
2010-09-01
Budget End
2012-08-31
Support Year
2
Fiscal Year
2010
Total Cost
$765,000
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Pharmacology
Type
Schools of Medicine
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Sampson, Catherine M; Kasper, James M; Felsing, Daniel E et al. (2018) Small-Molecule Neuromedin U Receptor 2 Agonists Suppress Food Intake and Decrease Visceral Fat in Animal Models. Pharmacol Res Perspect 6:e00425
Ali, Syed R; Liu, Zhiqing; Nenov, Miroslav N et al. (2018) Functional Modulation of Voltage-Gated Sodium Channels by a FGF14-Based Peptidomimetic. ACS Chem Neurosci 9:976-987
Liu, Zhiqing; Tian, Bing; Chen, Haiying et al. (2018) Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur J Med Chem 151:450-461
Xu, Jimin; Wold, Eric A; Ding, Ye et al. (2018) Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection. Molecules 23:
Chen, Zekun; Wu, Qiuju; Ding, Ye et al. (2017) YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway. Theranostics 7:2339-2349
Li, Rui; Ding, Chunyong; Zhang, Jun et al. (2017) Modulation of Bax and mTOR for Cancer Therapeutics. Cancer Res 77:3001-3012
McCue, D L; Kasper, J M; Hommel, J D (2017) Regulation of motivation for food by neuromedin U in the paraventricular nucleus and the dorsal raphe nucleus. Int J Obes (Lond) 41:120-128
Liu, Zhiqing; Wang, Pingyuan; Chen, Haiying et al. (2017) Drug Discovery Targeting Bromodomain-Containing Protein 4. J Med Chem 60:4533-4558
Wang, Yu; Wang, Sinan; Wu, Yansheng et al. (2017) Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/?-catenin Axis with HJC0152. Mol Cancer Ther 16:578-590
Liu, Zhiqing; Wild, Christopher; Ding, Ye et al. (2016) BH4 domain of Bcl-2 as a novel target for cancer therapy. Drug Discov Today 21:989-96

Showing the most recent 10 out of 43 publications